|
Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). |
|
|
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical |
|
|
Employment - HealthONE; Sarah Cannon Research Institute |
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; BeiGene; Biothera; Celgene; Curegenix; Curis; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; Hutchison MediPharma; Ignyta; Incyte; Jounce Therapeutics; Kolltan Pharmaceuticals; Lilly; Loxo; MedImmune; Merck; Millennium; Novartis; OncoMed; Precision Oncology; Regeneron; Rgenix; Strategia Therapeutics; Syndax; Taiho Pharmaceutical; Takeda; Tarveda Therapeutics; Tarveda Therapeutics; Tesaro; Tocagen; Vegenics |
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Millennium; Sarah Cannon Research Institute |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Multiple pharmaceutical/biotech companies |
|
|
Employment - Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Taiho Pharmaceutical |
|
|
|
Leadership - Orra Group; TEQ Analytic Laboratories |
Stock and Other Ownership Interests - amidebio; TEQ Analytic Laboratories |
Consulting or Advisory Role - Agios; Bayer; Clinipace; Deciphera; Fluidigm; Globavir; HERON; igm; miRagen; Pre-Cell; Prevacept; Taiho Pharmaceutical |
Patents, Royalties, Other Intellectual Property - milestone payments on dengue vaccine development from Takeda |
Travel, Accommodations, Expenses - Orra Group |
|
|
Research Funding - Abbott/AbbVie (Inst); ADC Therapeutics (Inst); Agios (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst) |
Travel, Accommodations, Expenses - Celgene; Daiichi Sankyo; Merck; Roche/Genentech |